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Objectives: Several randomized controlled trials have compared 
adrenaline (epinephrine) with alternative therapies in patients with 
cardiac arrest with conflicting results. Recent observational stud-
ies suggest that adrenaline might increase return of spontaneous 
circulation but worsen neurologic outcome. We systematically 
compared all the vasopressors tested in randomized controlled 
trials in adult cardiac arrest patients in order to identify the treat-
ment associated with the highest rate of return of spontaneous 
circulation, survival, and good neurologic outcome.
Design: Network meta-analysis.
Patients: Adult patients undergoing cardiopulmonary resuscitation.
Interventions: PubMed, Embase, BioMed Central, and the 
Cochrane Central register were searched (up to April 1, 2017). 
We included all the randomized controlled trials comparing a 
vasopressor with any other therapy. A network meta-analysis with 
a frequentist approach was performed to identify the treatment 
associated with the highest likelihood of survival.
Measurements and Main Results: Twenty-eight studies randomizing 
14,848 patients in 12 treatment groups were included. Only a com-
bined treatment with adrenaline, vasopressin, and methylprednisolone 
was associated with increased likelihood of return of spontaneous cir-
culation and survival with a good neurologic outcome compared with 
several other comparators, including adrenaline. Adrenaline alone was 
not associated with any significant difference in mortality and good 
neurologic outcome compared with any other comparator.
Conclusions: In randomized controlled trials assessing vasopressors in 
adults with cardiac arrest, only a combination of adrenaline, vasopres-
sin, and methylprednisolone was associated with improved survival 
with a good neurologic outcome compared with any other drug or pla-
cebo, particularly in in-hospital cardiac arrest. There was no significant 
randomized evidence to support neither discourage the use of adrena-
line during cardiac arrest. (Crit Care Med 2018; 46:e443–e451)
Key Words: adrenaline; cardiac arrest; resuscitation; return of 
spontaneous circulation; survival; vasopressin
Cardiac arrest is the most severe medical emergency; despite wide efforts to improve outcome, only a minor-ity of resuscitated patients is discharged in good neuro-
logic condition.
Out-of-hospital cardiac arrest (OHCA) has an estimated 
occurrence rate of 55–113 cases yearly per 100,000 inhabit-
ants with crude survival rates ranging from 6% to 22% (1–5). 
In-hospital cardiac arrest (IHCA) has a reported occurrence 
rate of one to five cases every 1,000 patients (6–8), with sur-
vival rates of approximately 24% (9).
Current guidelines on cardiopulmonary resuscitation 
(CPR) and advanced life support (ALS) recommend the 
administration of 1 mg of adrenaline (epinephrine) via IV or 
intraosseous route every 3–5 minutes during resuscitation; 
however, this recommendation is based on expert opinion, and 
there is no direct evidence that adrenaline increases survival to 
hospital discharge (10). In addition, recent observational stud-
ies suggest that administration of adrenaline may increase the 
rate of return of spontaneous circulation (ROSC) but at the 
cost of a worse neurologic outcome in survivors (11).DOI: 10.1097/CCM.0000000000003049
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Several randomized controlled trials (RCTs) have compared 
standard adrenaline with higher doses of adrenaline, alternative 
vasopressors (e.g., vasopressin), combinations of vasopressors, 
or placebo (12–17), with conflicting results. However, results 
of these trials have not been compared with each other in order 
to detect which pharmacologic strategy is the best (18).
A network meta-analysis (NMA) is a statistical technique 
that allows performing an indirect comparison between treat-
ments that have never been directly compared in randomized 
clinical trials (19–21).
Therefore, we performed a NMA to indirectly compare and 
grade all the vasopressor drugs tested in RCTs in adult patients 
with cardiac arrest in order to identify the treatment associated 
with the highest survival rate, the highest likelihood of ROSC, 
and the best neurologic outcome.
MATERIALS AND METHODS
We performed a systematic review and NMA according to the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement (PRISMA-NMA; checklist is 
available in Supplemental Digital Content 1, http://links.lww.
com/CCM/D314) (22–25).
Data Sources and Search Strategy
Relevant studies were searched on PubMed, Embase, BioMed 
Central, and the Cochrane Central register by two independent 
investigators. Our search strategy aimed to include every RCT 
investigating the use of a vasopressor agent in adult patients 
with cardiac arrest. In addition, we employed backward snow-
balling (i.e., scanning of references of retrieved articles and 
pertinent reviews) to identify further studies. Literature search 
was last updated April 1, 2017. The PubMed search strategy, 
modified from Biondi-Zoccai et al (26), is available in the 
supplementary appendix (Supplemental Digital Content 2, 
http://links.lww.com/CCM/D315).
Study Selection
Two investigators first examined references at a title/abstract 
level, and then, if potentially pertinent, retrieved the complete 
articles. All RCTs on adult patients in cardiac arrest, with at 
least one group randomized to receive a vasopressor, were con-
sidered for inclusion. Exclusion criteria were nonadult popu-
lation, overlapping population, lack of mortality data, study 
published as abstract only, and study investigating drugs not 
available on the market.
Data Extraction and Quality Assessment
Cardiac arrest setting, presentation rhythm, procedural, out-
come, and follow-up data were independently abstracted by 
two investigators. Patients randomized to placebo and those 
randomized to standard treatment were aggregated together 
as a single comparison group. After extraction of procedural 
data from studies comparing low-dose versus high-dose 
adrenaline (13, 27–34), we decided to define low- and high-
dose adrenaline as follows: low-dose adrenaline was less than 
or equal to 1 mg or 0.02 mg/kg (1.4 mg in a 70 kg person) and 
high-dose adrenaline was greater than or equal to 2 mg or 
0.1 mg/kg. This definition is consistent with results of animal 
trials performed in the late 80s and early 90s suggesting that 
adrenaline doses higher than 1 mg might results in improved 
outcome (35–40). Two independent investigators assessed the 
internal validity and risk of bias (at a study level) of included 
trials according to the “Risk of bias assessment tool” devel-
oped by The Cochrane collaboration (41), with divergences 
resolved by consensus.
Data Synthesis and Analysis
Primary outcome was survival at the longest follow-up avail-
able, whereas secondary outcomes were ROSC rate and sur-
vival with a good neurologic outcome at the longest follow-up 
available. Good neurologic outcome was defined as per 
Authors’ definition in each study (detailed in Table 1). Sub-
group analyses included patients with IHCA versus OHCA 
and patients with shockable versus nonshockable presenta-
tion rhythms.
Dichotomous variables were reported as percentages, 
whereas continuous variables were reported as mean ± 
sd or median (interquartile range). NMA with a frequen-
tist approach was used to compare mortality at the longest 
follow-up available between different therapies using the 
netmeta R package version 8.0 (available at: http://CRAN.R-
project.org/package=netmeta) to calculate point estimates 
of risk differences (RDs) with 95% CIs and generate head-
to-head comparison and forest plots using fixed-effects (in 
case of low heterogeneity/inconsistency) and random-effects 
models (in case of high heterogeneity/inconsistency) com-
paring the effect estimates of different therapies relative to 
low-dose adrenaline (21). P rank scores were generated to 
determine probability scores to rank which therapies result 
in the highest survival. Heterogeneity and inconsistency were 
assessed to generate heat plots, these are a matrix visualiza-
tion proposed by Krahn et al (56) that highlight hot spots of 
inconsistency between specific direct evidence in the whole 
network and allows to highlight possible drivers. Data were 
analyzed according to the intention-to-treat principle when-
ever possible. Statistical analysis was performed using R (21, 
57–60), with statistical significance for hypothesis testing set 
at the 0.05 two-tailed level and for heterogeneity testing at the 
0.10 two-tailed level.
RESULTS
Study Characteristics
The literature search yielded a total of 372 studies. Of these, 
325 were excluded at the title or abstract level because not rel-
evant to the study question or clearly meeting the exclusion 
criteria (e.g. nonrandomized studies, studies performed in set-
ting other than cardiac arrest, animal studies). A total of 19 
studies were then excluded due to prespecified criteria (Sup-
plementary Table 1, Supplemental Digital Content 2, http://
links.lww.com/CCM/D315). Finally, 28 studies randomizing 
14,848 patients in 12 treatment groups (comparators) were 
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TABLE 1. Survival With a Good Neurologic Outcome
References Investigated Treatments
Definition of  
Good Neurologic  
Outcome
Treatment 1, 
Good  
Outcome/n
Treatment 2, 
Good  
Outcome/n
Treatment 3,  
Good  
Outcome/n
Brown et al (27) Low-dose adrenaline vs high-dose 
adrenaline
CPC score 1–3 24/632 29/648  
Callaham et al (28) Low-dose adrenaline vs high-dose  
adrenaline vs noradrenaline
CPC score 1–2 27,260 0/286 0/270
Callaway et al (42) Low-dose adrenaline vs low-dose  
adrenaline + vasopressin
N/R N/R N/R  
Choux et al (29) Low-dose adrenaline vs high-dose  
adrenaline
Glasgow Coma Scale 
score 9–15
4/265 3/271  
Ducros et al (43) Low-dose adrenaline vs low-dose  
adrenaline + vasopressin vs low- 
dose adrenaline + vasopressin + 
nitroglycerin
CPC score 1–2 2/16 0/14 0/14
Ghafourian et al (44) Low-dose adrenaline vs low-dose  
adrenaline + vasopressin
N/R N/R N/R  
Gueugniaud et al (14) Low-dose adrenaline vs low-dose  
adrenaline + vasopressin
CPC score 1–2 20/1,452 13/1,442  
Gueugniaud et al (13) Low-dose adrenaline vs high-dose  
adrenaline
CPC score 1 26/1,938 26/1,969  
Jacobs et al (17) Low-dose adrenaline vs placebo CPC score 1–2 9/272 5/262  
Jaffe et al (45) Low-dose adrenaline vs low-dose  
adrenaline + isoproterenol
N/R N/R N/R  
Lindner et al (46) Low-dose adrenaline vs noradrenaline N/R N/R N/R  
Lindner et al (47) Low-dose adrenaline vs vasopressin N/R N/R N/R  
Lindner et al (30) Low-dose adrenaline vs high-dose  
adrenaline
N/R N/R N/R  
Lipman et al (31) Low-dose adrenaline vs high-dose  
adrenaline
N/R N/R N/R  
Mentzelopoulos et al (16) low-dose adrenaline vs AVM CPC score 1–2 5/154 11/146  
Mentzelopoulos et al (48) Low-dose adrenaline vs AVM CPC score 1–2 2/52 8/48  
Mukoyama et al (49) Low-dose adrenaline vs vasopressin CPC score 1–2 6/158 10/178  
Olson et al (50) Low-dose adrenaline vs methoxamine N/R N/R N/R  
Ong et al (51) Low-dose adrenaline vs vasopressin CPC score 1–2 5/353 5/374  
Patrick et al (15) High-dose adrenaline vs methoxamine Mean value Glasgow- 
Pittsburgh Coma 
Scale
N/R N/R  
Sherman et al (32) Low-dose adrenaline vs high-dose  
adrenaline
CPC score 1–2 0/62 0/78  
Silfvast et al (52) Low-dose adrenaline vs phenylephrine N/R N/R N/R  
Stiell et al (53) Low-dose adrenaline vs vasopressin CPC score 1–2 13/96 10/104  
Stiell et al (33) Low-dose adrenaline vs high-dose  
adrenaline
CPC score 1 15/333 9/317  
Turner et al (54) Low-dose adrenaline vs methoxamine CPC score 1–2 0/40 0/40  
Weaver et al (55) Low-dose adrenaline vs lidocaine N/R N/R N/R  
Wenzel et al (12) Low-dose adrenaline vs vasopressin CPC score 1–2 28/597 22/589  
Woodhouse et al (34) High-dose adrenaline vs placebo CPC score 1–2 0/94 0/100  
AVM = adrenaline-vasopressin-methylprednisolone, CPC = Cerebral Performance Category, N/R = not reported. 
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included in the final analysis (flow-chart for trial inclusion is 
described in Fig. 1) (12–17, 27–34, 42–55). The characteristics 
of included trials are described in Supplementary Tables 2 
and 3 (Supplemental Digital Content 2, http://links.lww.com/
CCM/D315).
Twenty-six of 28 the included studies randomized patients 
into two treatment groups, whereas two studies randomized 
patients into three treatment 
groups (28, 43). Thereby, a 
total of 58 treatment arms 
were analyzed. The most fre-
quently investigated compara-
tors were low-dose adrenaline 
(7,211 patients in 26 treatment 
arms), high-dose adrenaline 
(3,328 patients in 10 treat-
ment arms), a combination 
of adrenaline plus vasopressin 
(1,673 patients in four treat-
ment arms), and a combina-
tion treatment of adrenaline, 
vasopressin, and methylpred-
nisolone (206 patients in two 
treatment arms). The com-
plete list of treatment arms is 
reported in Supplementary 
Tables 2 and 3 (Supplemental 
Digital Content 2, http://
links.lww.com/CCM/D315). 
Network configuration is pre-
sented in Figure 2.
Seven studies were judged 
to be at low risk of bias (12, 16, 
31, 42, 47, 48, 53), 10 studies at unclear risk of bias (13, 14, 
17, 30–32, 42, 49, 50, 53), and 11 studies at high risk of bias 
(15, 27–29, 34, 44–46, 49, 52, 55) (Supplementary Table 4, 
Supplemental Digital Content 2, http://links.lww.com/CCM/
D315).
Quantitative Data Synthesis
Overall Survival. Among the 12 treatments analyzed, the com-
bination of adrenaline, vasopressin and methylprednisolone 
(16, 41) was associated with increased likelihood of survival as 
compared with low-dose adrenaline (RD vs low-dose adrenaline, 
0.06; 95% CI, 0.01–0.11) (Supplementary Table 5, Supplemental 
Digital Content 2, http://links.lww.com/CCM/D315; and Sup-
plementary Fig. 1, Supplemental Digital Content 2, http://links.
lww.com/CCM/D315). Rank analysis showed that this combina-
tion had the highest probability to be the best treatment in terms 
of survival, followed by noradrenaline (norepinephrine), vaso-
pressin, phenylephrine and low-dose adrenaline (Table 2).
Network head-to-head comparison showed that the com-
bination of adrenaline, vasopressin and methylprednisolone 
(16, 41) was associated with an increased survival when com-
pared also to high-dose adrenaline, vasopressin, the combi-
nation of adrenaline-vasopressin, methoxamine, and placebo 
(Supplementary Table 5, Supplemental Digital Content 2, 
http://links.lww.com/CCM/D315). Heterogeneity among stud-
ies was low (tau2 < 0.0001; I2 = 0%; Q statistics p = 0.50). Heat 
plot is presented in Supplementary Figure 8 (Supplemental 
Digital Content 2, http://links.lww.com/CCM/D315).
ROSC. Rank analysis showed that adrenaline-vasopressin-
methylprednisolone had the highest probability to be the best 
Figure 1. Flow-chart for included studies. CPR = cardiopulmonary resuscitation.
Figure 2. Network configuration. Adr = adrenaline, AVM = adrenaline + 
vasopressin + methylprednisolone, HD = high dose, Iso = isoproterenol, 
LD = low dose, Lido = lidocaine, Mtx = methoxamine, Nor = noradrenaline,  
Ntg = nitroglycerin, Phe = phenylephrine, Plac = placebo, Vas = vasopressin.
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pharmacologic treatment, followed by noradrenaline and 
high-dose adrenaline, phenylephrine, and vasopressin.
Head-to-head comparison showed an increased probabil-
ity of ROSC with adrenaline-vasopressin-methylprednisolone 
compared with high-dose adrenaline, vasopressin, adrenaline-
vasopressin, methoxamine, and placebo. Conversely, methox-
amine reduced ROSC probability compared with high-dose 
adrenaline, vasopressin, and noradrenaline (Supplementary 
Tables 6 and 11, Supplemental Digital Content 2, http://
links.lww.com/CCM/D315; and Supplementary Fig. 2, 
Supplemental Digital Content 2, http://links.lww.com/CCM/
D315). Heterogeneity among studies was high (tau2 = 0.0025; 
I2 = 61.4%; Q statistics p = 0.0003).
Good Neurologic Outcome. Using low-dose adrenaline as 
reference, only the combination of adrenaline, vasopressin, 
and methylprednisolone was associated with increased survival 
with a good neurologic outcome (RD vs low-dose adrenaline, 
0.06; 95% CI, 0.01–0.10). Head-to-head network comparison 
showed increased survival with good neurologic outcome when 
adrenaline-vasopressin-methylprednisolone was compared with 
high-dose adrenaline, vasopressin, adrenaline-vasopressin, nor-
adrenaline, and placebo (Supplementary Tables 7 and 12, Sup-
plemental Digital Content 2, http://links.lww.com/CCM/D315; 
and Supplementary Fig. 3, Supplemental Digital Content 2, 
http://links.lww.com/CCM/D315). Heterogeneity among stud-
ies was low (tau2 < 0.0001; I2 = 0%; Q statistics p = 0.69).
IHCA and OHCA. When analyzing studies investigating 
OHCA, no treatment was associated with increased survival 
compared with others (Supplementary Tables 10 and 15, Sup-
plemental Digital Content 2, http://links.lww.com/CCM/D315; 
and Supplementary Fig. 6, Supplemental Digital Content 2, 
http://links.lww.com/CCM/D315). Heterogeneity among stud-
ies was low (tau2 < 0.0001; I2 = 0%; Q statistics p = 0.50).
Considering IHCA, the combination of adrenaline, vaso-
pressin, and methylprednisolone was associated with increased 
survival compared with low-dose adrenaline (RD, 0.06; 95% 
CI, 0.01–0.11). Head-to-head comparison showed increased 
survival associated with adrenaline-vasopressin-methylpred-
nisolone treatment when compared with high-dose adrena-
line (RD, 0.07; 95% CI, 0.01–0.14) (Supplementary Tables 11 
and 16, Supplemental Digital Content 2, http://links.lww.
com/CCM/D315; and Supplementary Fig. 7, Supplemental 
Digital Content 2, http://links.lww.com/CCM/D315). 
Heterogeneity among studies was moderate (tau2 = 0.0012; I2 
= 30.5%; Q statistics p = 0.23).
Outcomes According to Initial Rhythm. When analyzing 
treatments for cardiac arrest with an initial shockable rhythm, 
we found that no treatment was superior to another in terms of 
survival. Heterogeneity among studies was low (tau2 = 0.0003; 
I2 = 12.8%; Q statistics p = 0.33) (Supplementary Tables 8 
and 13, Supplemental Digital Content 2, http://links.lww.com/
CCM/D315; and Supplementary Fig. 4, Supplemental Digital 
Content 2, http://links.lww.com/CCM/D315).
Similarly, no treatment was associated with increased sur-
vival when analyzing data on cardiac arrest with a nonshock-
able rhythm at presentation (Supplementary Tables 9 and 14, 
Supplemental Digital Content 2, http://links.lww.com/CCM/
D315; and Supplementary Fig. 5, Supplemental Digital Content 
2, http://links.lww.com/CCM/D315). Heterogeneity among 
studies was low (tau2 < 0.0001; I2 = 0%; Q statistics p = 0.60).
DISCUSSION
In this large NMA of randomized trials investigating vasopres-
sors during CPR, we found that only a combined treatment with 
adrenaline, vasopressin, and methylprednisolone (16, 48) was asso-
ciated with a significantly higher likelihood of ROSC, survival, and 
good neurologic outcome compared with low-dose adrenaline and 
to several other comparators. Conversely, methoxamine, an α
1
-
adrenergic agonist (61), was associated with reduced likelihood of 
ROSC. Considering IHCA, the combined treatment with adrena-
line, vasopressin, and methylprednisolone was once again the only 
treatment associated with increased survival; on the other hand, 
in OHCA, no treatment was found to be superior over the others.
Compared with previous systematic reviews and meta-anal-
yses published on the topic (62–67), this is the first study to 
compare and grade using a statistical analysis of the efficacy of 
all vasopressors tested during CPR in RCTs. In contrast, previ-
ous meta-analyses focused on single agents, usually adrenaline 
(63, 65, 66) or vasopressin (64, 67). The most comprehensive 
systematic (but not quantitative) review published so far by 
Larabee et al [62] in 2012 concluded that 1) adrenaline (both a 
low-dose and high-dose) provide a short-term benefit in terms 
of ROSC, 2) there are insufficient evidences to support or dis-
courage vasopressin use, and 3) noradrenaline may provide 
superior results in terms of ROSC compared with adrenaline. 
TABLE 2. Network Meta-Analysis Ranking  
of Treatments
Rank Treatment
Probability  
to Be  
the Best
1 Adrenaline + vasopressin + 
methylprednisolone
0.93
2 Noradrenaline 0.71
3 Vasopressin 0.63
4 Phenylephrine 0.62
5 Adrenaline—low dose 0.55
6 Lidocaine 0.53
7 Adrenaline—high dose 0.49
8 Placebo 0.36
9 Adrenaline + isoproterenol 0.35
10 Adrenaline + vasopressin 0.35
11 Adrenaline + vasopressin +  
nitroglycerin
0.31
12 Methoxamine 0.16
Treatments with highest ranking have the highest probability to be the best  
in terms of survival.
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A major difference with our study is that Larabee et al (62) did 
not perform a statistical analysis of their results.
The most widely investigated alternative to adrenaline has 
been vasopressin. Current evidence concerning vasopressin use 
in cardiac arrest shows no survival benefit in unselected patients. 
A meta-analysis by Mentzelopoulos et al (67) published in 2012 
showed that vasopressin versus control was associated with 
higher long-term survival only in patients with asystole, espe-
cially when the drug was administered within 20 minutes from 
arrest. In 2014, a meta-analysis from Layek et al (64) showed that 
vasopressin was associated with an increased likelihood of ROSC 
when the drug was used in the setting of IHCA and an increased 
likelihood of survival to hospital discharge and survival with a 
favorable neurologic outcome when vasopressin was admin-
istered as “repeated boluses of 4–5 times titrated to the desired 
effects.” We found no significant increase in the rate of ROSC or 
survival to the longest follow-up available when vasopressin was 
used compared with other agents. The most likely explanation for 
these differences is that results of the meta-analysis by Layek et 
al (64) are significantly influenced by the two studies performed 
by Mentzelopoulos et al (16, 48), which were analyzed together 
with studies on vasopressin. In contrast, in our study, we grouped 
these two RCTs separately since the administration of vasopres-
sin was combined to adrenaline and methylprednisolone, and the 
study design also included a postresuscitation treatment.
In their meta-analysis of RCTs and observational trials on 
adrenaline use during CPR, Patanwala et al (65) found that 
adrenaline was associated with decreased survival after cardiac 
arrest. However, their analysis included observational studies, 
subjected to higher risk of bias than RCTs, that mainly influenced 
the results. Differently from that study, we included only RCTs.
In our study, we were able to identify a treatment that, com-
pared with all other vasopressors administered during CPR 
ever tested in RCTs, was shown to increase survival with a good 
neurologic outcome. Differently from previous literature, our 
results are for the first time supported by a statistical approach 
indirectly comparing the efficacy of all treatments ever assessed 
in RCTs. However, we acknowledge that these results are mainly 
driven by two studies by Mentzelopoulos et al (16), which were 
performed in the setting of IHCA, with a relevant proportion of 
patients being already in an ICU, where all equipment for ALS 
and postresuscitation care are readily available, and the staff is well 
trained in the management of cardiac arrest. Another possible 
explanation for the positive results obtained by Mentzelopoulos 
et al (16) is the effect of steroids on postresuscitation syndrome. 
Steroids administration could attenuate postarrest systemic 
inflammatory response syndrome (68, 69). In addition, release 
of adrenal hormone is frequently impaired after cardiac arrest, 
which reduces the physiologic stress response (70, 71). Finally, 
steroids may increase response to vasopressors due to their effect 
on intracellular signaling pathways (72). Notably, the protocol 
investigated by Mentzelopoulos et al (16) does not allow to dis-
tinguish between effects of steroids administration during versus 
after CPR, as patients in the treatment groups received steroids 
in both phases. Nevertheless, a recent multicenter RCT enrolling 
patients with refractory shock following cardiac arrest showed no 
difference in terms of shock reversal, good neurologic outcome, 
or survival to discharge between patients receiving hydrocorti-
sone or placebo (73). These results suggest that the positive effects 
found by Mentzelopoulos et al (16) may derive from vasopressin 
and methylprednisolone administration during CPR, rather than 
hydrocortisone administration after resuscitation.
Current ALS guidelines recommend administration of 1 mg 
adrenaline during CPR (10). This recommendation is based on 
low quality of evidence, in particular on old, nonrandomized 
trials, and has been part of resuscitation guidelines for decades 
(74). Although in our study we found that only adrenaline-
vasopressin-methylprednisolone combination was associated 
with increased survival, results of ranking analysis provide 
some interesting clues. Low-dose adrenaline was ranked only 
fifth, behind adrenaline-vasopressin-methylprednisolone, 
noradrenaline, and phenylephrine, whereas the combination 
adrenaline-vasopressin was ranked only tenth. This suggests 
that the two most widely used and investigated vasopressors or 
combination of vasopressors may not necessarily be the most 
effective in terms of potential impact on survival.
Interestingly, adrenaline (a potent β- and α-adrenergic agonist) 
was ranked below noradrenaline (which has higher affinity for 
α-adrenergic receptors than for β-receptors) and phenylephrine 
(a pure α-adrenergic agonist). Currently, several nonrandomized 
studies have questioned the benefit of adrenaline administration 
during CPR with worse neurologic outcome in patients receiv-
ing adrenaline, even in the face of an increased ROSC (11, 75–78). 
This has been explained by some authors with a detrimental effect 
of β-adrenergic stimulation on postresuscitation myocardial 
function and cerebral perfusion during CPR (79–81). However, 
other studies did not confirm these findings (82, 83), and a small 
study showed increased cerebral oxygenation following adrena-
line administration (84). In our study, we found no evidence of 
worse outcome associated with either high- or low-dose adrena-
line. However, it should be noted that most of the studies com-
pared adrenaline with another vasopressor, and use of open-label, 
low-dose adrenaline was generally allowed at some point of CPR 
algorithm in most of the studies. An ongoing randomized trial will 
hopefully provide a definitive answer on the role of prehospital 
adrenaline administration (Pre-hospital Assessment of the Role of 
Adrenaline: Measuring the Effectiveness of drug administration in 
Cardiac arrest [PARAMEDIC-2]: [ISRCTN73485024]) (85).
Nevertheless, in absence of adequately powered and high-quality 
RCTs, we believe that clinicians should follow current international 
guidelines provided by professional societies (10, 86), although 
application of the adrenaline-vasopressin–methylprednisolone 
protocol might be considered in the ICU setting. External validity 
and reproducibility of positive results obtained by Mentzelopoulos 
et al (16) and feasibility of their protocol outside the ICU should 
be confirmed in additional pragmatic international mRCTs, before 
widespread use could be recommended (87, 88).
A strength of our study is that we systematically searched 
and included only RCTs performed on this topic. In contrast 
to previous reviews and meta-analyses, our network meta-
analytic statistical approach allowed us to indirectly compare 
all the vasopressors used in RCT among each other.
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Our study has some limitations. First, we included stud-
ies performed in both OHCA and IHCA settings. However, we 
performed specific subgroup analyses for the different settings 
showing that the positive results of a combined treatment of 
vasopressin, adrenaline, and methylprednisolone arise from two 
studies performed by Mentzelopoulos et al in IHCA. Second, the 
quality of included trials was heterogeneous, with the majority of 
trials carrying an unclear or a high risk of bias. Our analysis focus-
ing on ROSC highlighted a high heterogeneity between studies, 
which limits the validity of this specific analysis. We hypothesize 
that heterogeneity is most likely due to case mix, ancillary treat-
ments, and possibly different ROSC definitions. However, we 
believe that this secondary analysis provides interesting clues to 
support future investigations on the most effective treatments. 
The definition of good neurologic outcome is not consistent 
across all included studies, although all but two define good 
neurologic outcome as Cerebral Performance Category score 1 
or 2, in line with current recommendations (89). Finally, all lim-
itations of meta-analyses apply also to network meta-analyses 
(20, 23, 90). In particular, meta-analyses should be considered 
hypothesis generating, particularly when available trials are het-
erogeneous or with high risk of bias.
CONCLUSIONS
This NMA of RCTs found that only a combined treatment with 
adrenaline, vasopressin, and methylprednisolone was associated 
with improved survival with a good neurologic outcome and ROSC 
probability compared with several other comparators, including 
adrenaline, particularly in IHCA. No significant randomized evi-
dences support neither discourage the use of adrenaline during 
cardiac arrest. High-quality studies are needed to confirm these 
findings and explore further therapeutic treatments in this setting.
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